share_log

Vivos Therapeutics | UPLOAD: Others

Vivos Therapeutics | UPLOAD: Others

Vivos Therapeutics | UPLOAD：其他
美股sec公告 ·  04/12 12:56
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a company listed in the US under the stock code VVOS, has been informed by the United States Securities and Exchange Commission (SEC) that its recently filed Registration Statement on Form S-1 will not undergo review. The statement, filed on April 9, 2024, with the file number 333-278564, was acknowledged by the SEC in a letter addressed to R. Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics. The SEC's correspondence, dated April 12, 2024, also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. The SEC's Division of Corporation Finance, Office of Industrial Applications and Services, directed any further questions to Jane Park and provided her contact information.
Vivos Therapeutics, Inc., a company listed in the US under the stock code VVOS, has been informed by the United States Securities and Exchange Commission (SEC) that its recently filed Registration Statement on Form S-1 will not undergo review. The statement, filed on April 9, 2024, with the file number 333-278564, was acknowledged by the SEC in a letter addressed to R. Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics. The SEC's correspondence, dated April 12, 2024, also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. The SEC's Division of Corporation Finance, Office of Industrial Applications and Services, directed any further questions to Jane Park and provided her contact information.
美国证券交易委员会（SEC）已通知Vivos Therapeutics, Inc. 是一家在美国上市的公司，股票代码为VVOS，该公司最近提交的S-1表格注册声明将不接受审查。该声明于2024年4月9日提交，文件编号为333-278564，美国证券交易委员会在给Vivos Therapeutics首席执行官柯克·亨斯曼的信中予以确认。美国证券交易委员会在2024年4月12日的信函中还提到了与加快注册程序的请求有关的第460和461条。美国证券交易委员会提醒该公司及其管理层，无论美国证券交易委员会的审查水平如何，他们都有责任确保披露的准确性和充分性。美国证券交易委员会工业应用与服务办公室公司财务处向简·帕克提出了任何进一步的问题，并提供了她的联系信息。
美国证券交易委员会（SEC）已通知Vivos Therapeutics, Inc. 是一家在美国上市的公司，股票代码为VVOS，该公司最近提交的S-1表格注册声明将不接受审查。该声明于2024年4月9日提交，文件编号为333-278564，美国证券交易委员会在给Vivos Therapeutics首席执行官柯克·亨斯曼的信中予以确认。美国证券交易委员会在2024年4月12日的信函中还提到了与加快注册程序的请求有关的第460和461条。美国证券交易委员会提醒该公司及其管理层，无论美国证券交易委员会的审查水平如何，他们都有责任确保披露的准确性和充分性。美国证券交易委员会工业应用与服务办公室公司财务处向简·帕克提出了任何进一步的问题，并提供了她的联系信息。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息